The study found that the level of plasma EMPs was decreased significantly in DM patients with hyperlipidemia and high angiopoietin-2 (Ang-2) level (Ang-2 ≥ 3.6 ng/mL) after 6 months of eicosapentaenoic acid (EPA) treatment. The gene discussed is ANGPT2; the disease is diabetes mellitus.